ROLE OF CELL WALL INTEGRITY IN ECHINOCANDIN RESISTANCE IN C. NEOFORMANS
细胞壁完整性在新型隐球菌棘白菌素抗性中的作用
基本信息
- 批准号:9927587
- 负责人:
- 金额:$ 38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-06-26 至 2022-05-31
- 项目状态:已结题
- 来源:
- 关键词:Africa South of the SaharaAmphotericin BAnabolismAntifungal AgentsAntifungal TherapyAntiviral AgentsAreaBiochemicalCandidate Disease GeneCell CommunicationCell MaintenanceCell WallCellsCessation of lifeCryptococcosisCryptococcusCryptococcus neoformansCyclic AMPCyclic AMP-Dependent Protein KinasesDataDefectDetectionDevelopmentDiseaseDrug TargetingFluconazoleFutureGene ActivationGene DeletionGene ProteinsGene TargetingGenesGeneticGenetic TranscriptionGenomicsGlucansGoalsHIVHIV SeropositivityHeat-Shock ResponseHomeostasisHumanImmunocompromised HostIndividualInfectionLeadMaintenanceMammalsMeasurableMolecularNatural ResistanceNew AgentsOxidative StressPathway AnalysisPathway interactionsPatientsPhenotypePhosphotransferasesPlayProtein KinaseProtein Kinase CProteinsRegulationRegulatory PathwayRelapseResistanceRoleSignal PathwayStressStructural ProteinToxic effectTuberculosisVirulenceburden of illnesscapsulecell growth regulationdeletion librarydesignechinocandin resistanceenzyme structurefungusgenetic regulatory proteinhuman pathogeninhibitor/antagonistmortalitynitrosative stressnovelnovel therapeuticspathogenic funguspreventrepairedresponsescreeningsynergismtranscription factor
项目摘要
Abstract:
Cryptococcus neoformans is a pathogenic fungus that is found world-wide and causes meningioencephalitis,
particularly in immunocompromised individuals. It is invariably fatal unless treated, and the current antifungals
are inadequate to effectively cure this disease, due to inherent toxicities, the inability to kill the fungus and
prevent relapse, or innate resistance to the class of antifungals. Recent studies have indicated that there are
over 1,000,000 new cases of cryptococcosis in the world each year, which results in over 600,000 deaths.
New agents to treat Cryptococcus are needed, and the fungal cell wall is an attractive target, since it is unique
to fungi and absent in humans.
Echinocandins are a class of antifungals that target glucan synthesis in the cell wall. Cryptococcus is naturally
resistant to the echinocandins. We have shown that disruption of the cell wall integrity (CWI) signaling pathway
causes Cryptococcus to become highly sensitive to echinocandins, and identified candidate transcription
factors that may play a role in echinocandin resistance. This pathway is the major pathway that impacts cell
wall and is dependent on protein kinase C (Pkc1). The CWI/PKC1 pathway plays a key role in response to
heat shock, oxidative and nitrosative stress, and cell wall inhibitors. Our preliminary data suggests that this
pathway is part of a highly connected network that controls cell wall biosynthesis, repair and remodeling. The
major goal of this project is to define the mechanism(s) by which cell wall integrity is maintained in response to
specific cell wall inhibitors, including echinocandins and to identify potential gene targets for antifungals with
synergy to echinocandins. There are three specific aims:
In the first aim, we will define the role of the cell wall integrity pathway in echinocandin resistance using
genomic and network analysis approaches. In the second aim, we will identify the genes essential to cell wall
integrity and that contribute to echinocandin resistance by screening large deletion sets for specific
phenotypes. In the third aim, we will assess the functional interactions of the cell wall integrity components.
In this highly collaborative project, we propose to use our complementary expertise to integrate genetic,
phenotypic and biochemical data to identify and characterize the network of interactions governing cell wall
homeostasis in C. neoformans. This will significantly advance our understanding of cell wall maintenance and
remodeling in a human pathogen and will provide multiple targets for designing specific antifungal drugs that
are less likely to be toxic in mammals.
摘要:
新型隐球菌是一种在世界范围内发现的致病真菌,可引起脑膜脑炎,
特别是在免疫功能低下的个体中。除非治疗,否则它总是致命的,目前的抗真菌药物
由于固有的毒性,不能杀死真菌,
防止复发,或对抗真菌药的先天耐药性。最近的研究表明,
全世界每年有超过1,000,000例新的隐球菌病病例,导致超过600,000人死亡。
需要新的药物来治疗隐球菌,真菌细胞壁是一个有吸引力的目标,因为它是独特的
而在人类中是不存在的
棘白菌素是一类靶向细胞壁中葡聚糖合成的抗真菌剂。隐球菌自然是
对棘白菌素有抵抗力我们已经表明,细胞壁完整性(CWI)信号通路的破坏,
导致隐球菌对棘白菌素高度敏感,
可能在棘白菌素耐药性中发挥作用的因素。该途径是影响细胞的主要途径,
它依赖于蛋白激酶C(Pkc 1)。CWI/PKC 1通路在应答
热休克、氧化和亚硝化应激以及细胞壁抑制剂。我们的初步数据表明,
信号通路是控制细胞壁生物合成、修复和重塑的高度连接网络的一部分。的
本项目的主要目标是确定细胞壁完整性维持的机制,
特异性细胞壁抑制剂,包括棘白菌素,并确定抗真菌药物的潜在基因靶点,
与棘白菌素的协同作用有三个具体目标:
在第一个目标中,我们将使用细胞壁完整性途径来定义棘白菌素抗性中的作用。
基因组和网络分析方法。在第二个目标中,我们将确定细胞壁所必需的基因
完整性和通过筛选大缺失组特异性
表型在第三个目标中,我们将评估细胞壁完整性组件的功能相互作用。
在这个高度合作的项目中,我们建议利用我们互补的专业知识,
表型和生化数据,用于识别和表征控制细胞壁的相互作用网络
C.新人类这将大大促进我们对细胞壁维护的理解,
在人类病原体中重塑,并将为设计特异性抗真菌药物提供多个靶点,
对哺乳动物的毒性较小。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Maureen J Donlin其他文献
Maureen J Donlin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Maureen J Donlin', 18)}}的其他基金
ROLE OF CELL WALL INTEGRITY IN ECHINOCANDIN RESISTANCE IN C. NEOFORMANS
细胞壁完整性在新型隐球菌棘白菌素抗性中的作用
- 批准号:
9237001 - 财政年份:2017
- 资助金额:
$ 38万 - 项目类别:
ROLE OF CELL WALL INTEGRITY IN ECHINOCANDIN RESISTANCE IN C. NEOFORMANS
细胞壁完整性在新型隐球菌棘白菌素抗性中的作用
- 批准号:
10626232 - 财政年份:2017
- 资助金额:
$ 38万 - 项目类别:
ANALYSIS OF MUTATOR TRANSPOSON DEVELOPMENTAL REGULATION
突变转座子发育调控分析
- 批准号:
2170370 - 财政年份:1993
- 资助金额:
$ 38万 - 项目类别:
相似海外基金
有機分子触媒を用いたAmphotericin Bの合成研究
有机分子催化剂合成两性霉素B的研究
- 批准号:
24K17671 - 财政年份:2024
- 资助金额:
$ 38万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
EnLAmB - Enabling global access to affordable generic liposomal amphotericin B injectable formulations via advanced manufacturing technology
EnLAmB - 通过先进的制造技术,使全球能够获得负担得起的通用脂质体两性霉素 B 注射制剂
- 批准号:
MR/X014010/1 - 财政年份:2023
- 资助金额:
$ 38万 - 项目类别:
Research Grant
Integrating genome-wide association study, quantitative trait loci mapping and transcriptome sequencing to identify genes associated with amphotericin B resistance in Aspergillus fumigatus
整合全基因组关联研究、数量性状基因座作图和转录组测序,鉴定与烟曲霉两性霉素 B 耐药性相关的基因
- 批准号:
559052-2021 - 财政年份:2022
- 资助金额:
$ 38万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Study on naturally-occurring peptides potentiating amphotericin B activity
天然存在的肽增强两性霉素 B 活性的研究
- 批准号:
22K05333 - 财政年份:2022
- 资助金额:
$ 38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrating genome-wide association study, quantitative trait loci mapping and transcriptome sequencing to identify genes associated with amphotericin B resistance in Aspergillus fumigatus
整合全基因组关联研究、数量性状基因座作图和转录组测序,鉴定与烟曲霉两性霉素 B 耐药性相关的基因
- 批准号:
559052-2021 - 财政年份:2021
- 资助金额:
$ 38万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Amphotericin B Restoration of Anion Secretion in Cystic Fibrosis Airways
两性霉素 B 恢复囊性纤维化气道阴离子分泌
- 批准号:
10024667 - 财政年份:2020
- 资助金额:
$ 38万 - 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
- 批准号:
9909193 - 财政年份:2020
- 资助金额:
$ 38万 - 项目类别:
Amphotericin B Restoration of Anion Secretion in Cystic Fibrosis Airways
两性霉素 B 恢复囊性纤维化气道阴离子分泌
- 批准号:
10248529 - 财政年份:2020
- 资助金额:
$ 38万 - 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
- 批准号:
10484014 - 财政年份:2020
- 资助金额:
$ 38万 - 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
- 批准号:
10654834 - 财政年份:2020
- 资助金额:
$ 38万 - 项目类别:














{{item.name}}会员




